Back to Report Store Home

Global Neurodegenerative Drugs Market to 2022 – Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

  • Published: Dec-2016
  • Report Code: GBIHC425MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Neurodegenerative Disorders, Seven Major Markets, Epidemiology Patterns for Alzheimer’s Disease (‘000), 2015–2022 24

Figure 2: Neurodegenerative Disorders, Seven Major Markets, Epidemiology Patterns for Parkinson’s Disease (‘000), 2015–2022 25

Figure 3: Neurodegenerative disorders, Seven Major Markets, Epidemiology Patterns for Huntington’s Disease (‘000), 2015–2022 26

Figure 4: Neurodegenerative Disorders, Seven Major Markets, Epidemiology Patterns for Amyotrophic Lateral Sclerosis (‘000), 2015–2022 27

Figure 5: Neurodegenerative disorders, Seven Major Markets, Epidemiology Patterns for Multiple Sclerosis (‘000), 2015–2022 28

Figure 6: Neurodegenerative Disorders, Global, Key Marketed Products and Approved Indications, 2016 35

Figure 7: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Tecfidera ($bn), 2013–2022 37

Figure 8: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Copaxone ($bn), 2006–2022 39

Figure 9: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Tysabri ($bn), 2006–2022 41

Figure 10: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Gilenya ($bn), 2011–2022 43

Figure 11: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Avonex ($bn), 2006–2022 44

Figure 12: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Plegridy ($bn), 2014–2022 46

Figure 13: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Namenda/Namenda XR ($bn), 2006–2022 48

Figure 14: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Nuplazid ($bn), 2016–2022 50

Figure 15: Neurodegenerative Disorders Therapeutics Market, Global, Pipeline for Neurodegenerative Disorder by Stage of Development, Molecule Type and Program Type, 2016 52

Figure 16: Breakdown of Biologics in Neurodegenerative Disorders Pipeline, 2016 53

Figure 17: Neurodegenerative Disorders Therapeutics Market, Global, Pipeline for Key Neurodegenerative Disorder Indications by Stage of Development, 2016 54

Figure 18: Neurodegenerative Disorders Therapeutics Market, Pipeline by Mechanism of Action (%), 2016 55

Figure 19: Neurodegenerative Disorders Therapeutics Market, Global, Pipeline for Key Neurodegenerative Disorder Indications by Mechanism of Action, 2016 56

Figure 20: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2016 57

Figure 21: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2016 58

Figure 22: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2016 59

Figure 23: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2016 60

Figure 24: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2016 61

Figure 25: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2016 62

Figure 26: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2016 63

Figure 27: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2016 64

Figure 28: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006–2016 65

Figure 29: Neurodegenerative disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2015 66

Figure 30: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2016 67

Figure 31: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2016 68

Figure 32: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development (patients), 2006–2016 69

Figure 33: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2016 70

Figure 34: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2015 71

Figure 35: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2016 72

Figure 36: Neurodegenerative Disorders, Global, Annual Revenue for Ocrelizumab ($bn), 2016–2022 73

Figure 37: Neurodegenerative Disorders, Global, Annual Revenue for Ozanimod ($bn), 2018–2022 75

Figure 38: Neurodegenerative Disorders, Global, Annual Revenue for Solanezumab ($bn), 2017–2022 76

Figure 39: Neurodegenerative Disorders, Global, Annual Revenue for Crenezumab ($m), 2017–2022 78

Figure 40: Neurodegenerative Disorders, Global, Annual Revenue for Tirasemtiv ($m), 2019–2022 79

Figure 41: Neurodegenerative Disorders, Global, Annual Revenue for CVT-301 ($m), 2018–2022 80

Figure 42: Neurodegenerative Disorder Therapeutics Market, Global, Market Size ($bn), 2015–2022 82

Figure 43: Neurodegenerative Disorders, Global, Annual Revenue for Key Products ($m), 2014–2022 84

Figure 44: Neurodegenerative Disorders, Global, Annual Revenue for Immunomodulators ($bn), 2015–2022 85

Figure 45: Neurodegenerative Disorders, Global, Annual Revenue for Neuromodulators ($bn), 2015–2022 86

Figure 46: Neurodegenerative Disorders, Global, Annual Revenue for Amyloid Inhibitors ($bn), 2015–2022 86

Figure 47: Neurodegenerative Disorders, Global, Annual Revenue for APP inhibitors ($m), 2015–2022 87

Figure 48: Neurodegenerative Disorders Therapeutics Market, Global, Cluster by Growth and Market Share, 2015–2022 88

Figure 49: Neurodegenerative Disorders, Global, Market Share by Company (%), 2015–2022 91

Figure 50: Neurodegenerative Disorders, Global, Companies by Compound Annual Growth Rate (%), 2014–2022 92

Figure 51: Neurodegenerative Disorders, Global, Revenue by Product Type, 2015–2022 93

Figure 52: Neurodegenerative Disorders, Global, Biogen Annual Revenue ($bn), 2015–2022 94

Figure 53: Neurodegenerative Disorders, Global, Novartis Annual Revenue ($bn), 2015–2022 95

Figure 54: Neurodegenerative Disorders, Global, Roche Annual Revenue ($bn), 2015–2022 96

Figure 55: Neurodegenerative Disorders, Global, Sanofi Annual Revenue ($bn), 2015–2022 97

Figure 56: Neurodegenerative Disorders, Global, Teva Annual Revenue ($bn), 2015–2022 98

Figure 57: Neurodegenerative Disorders, Global, Acadia Annual Revenue ($bn), 2015–2022 99

Figure 58: Neurodegenerative Disorders, Global, AbbVie Annual Revenue ($m), 2015–2022 100

Figure 59: Neurodegenerative Disorders, Global, Eli Lilly Annual Revenue ($m), 2015–2022 101

Figure 60: Neurodegenerative Disorders, Global, Celgene Annual Revenue ($m), 2015–2022 102

Figure 61: Neurodegenerative Disorders, Global, Lundbeck Annual Revenue ($m), 2015–2022 103

Figure 62: Neurodegenerative Disorders, Global, Companies by Type, 2016 104

Figure 63: Neurodegenerative Disorders, Global, High-Activity and Late-Stage Pipeline Developers by Level of Neurodegenerative Disorders, 2016 105

Figure 64: Neurodegenerative Disorders, Global, Proportion of Total Company Revenue Attributed to Neurodegenerative Disorders, 2015–2022 106

Figure 65: Neurodegenerative Disorders, Global, Licensing Deals, 2006–2016 108

Figure 66: Neurodegenerative Disorders, Global, Licensing Deals by Indication and Value, 2006–2016 109

Figure 67: Neurodegenerative Disorders, Global, Licensing Deals, 2006–2016 110

Figure 68: Neurodegenerative Disorders, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006–2016 111

Figure 69: Neurodegenerative Disorders, Global, Co-development Deals, 2006–2016 116

Figure 70: Neurodegenerative Disorders, Global, Co-development Deals by Indication and Value, 2006–2016 117

Figure 71: Neurodegenerative Disorders, Global, Co-development Deals, 2006–2016 118

Figure 72: Neurodegenerative Disorders, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006–2016 119

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards